Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial - Pal, SK; Uzzo, R; Karam, JA (The Lancet, 2022)